We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Antriabio Announces Completion Of PK/PD Studies Of AB101

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Antriabio Announces Completion Of PK/PD Studies Of AB101 "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

AntriaBio, Inc. has successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. The studies assessed the receptor pharmacology, pharmacokinetics and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients. The current standard of care in the $10 billion basal insulin market is a daily treatment.

"Despite the many advancements in therapy, there remain many challenges for patients with diabetes that may be mitigated by the availability of new, longer acting basal insulin therapy," said C. Ronald Kahn, M.D., Chief Academic Officer and Past President of Joslin Diabetes Center, the world's largest diabetes clinical care and research organization. "If successful in human clinical studies and commercialized, AB101 could reduce the number of required injections and may even help transition insulin-averse patients and providers to earlier use of insulin."

AntriaBio is currently engaged in additional studies, including ongoing toxicology studies that would support the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for AB101 and the subsequent launch of a clinical study in type 1 diabetes patients this year.

The Company's Vice President of Clinical Development, Brian Roberts, M.D., stated, "We are emboldened by the completion of these animal studies, which represents an exciting milestone toward advancing AB101 into clinical trials."